Emerging nanomaterials for targeting subcellular organelles

被引:132
作者
Huang, Jasper G. [1 ]
Leshuk, Timothy
Gu, Frank X. [1 ]
机构
[1] Univ Waterloo, Dept Chem Engn, Waterloo Inst Nanotechnol, Waterloo, ON N2L 3G1, Canada
基金
加拿大自然科学与工程研究理事会; 日本学术振兴会;
关键词
Nucleus; Mitochondria; Endoplasmic reticulum; Golgi apparatus; Nanoparticles; Controlled release; Targeted therapy; DELIVERY;
D O I
10.1016/j.nantod.2011.08.002
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Over the past decade, research interest in the application of biomedical nanotechnology to the diagnosis and treatment of disease has grown significantly, and physiological barriers to nanoparticle delivery may now be rationally overcome. Subcellular targeting is defined as engineered nanoparticle intracellular interactions, processing, and trafficking, and is a rapidly developing frontier of biomedical innovation. The potential clinical impact of nanoparticle subcellular targeting may be appreciated when considering the promise of effective gene therapies, molecular imaging devices, and treatments for organelle-specific diseases. In this review, we discuss recent innovations in the materials, ligands, and methods employed in designing subcellular nanotechnology, from cellular internalization methods and endosomal escape to recent approaches used to target the nucleus, mitochondria, endoplasmic reticulum, Golgi apparatus, as well as other organelles and intracellular events. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:478 / 492
页数:15
相关论文
共 176 条
  • [1] Akita H., 2009, BIOMATERIALS, V30, P15
  • [2] Nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: Programmed endosomal escape and dissociation
    Akita, Hidetaka
    Kogure, Kentaro
    Moriguchi, Rumiko
    Nakamura, Yoshio
    Higashi, Tomoko
    Nakamura, Takashi
    Serada, Satoshi
    Fujimoto, Minoru
    Naka, Tetsuji
    Futaki, Shiroh
    Harashima, Hideyoshi
    [J]. JOURNAL OF CONTROLLED RELEASE, 2010, 143 (03) : 311 - 317
  • [3] Alber F., 2007, NATURE, V450, P7170
  • [4] Albumin-bound paclitaxel, ABI-007 may show better efficacy than paclitaxel in basal-like breast cancers: Association between caveolin-1 expression and ABI-007
    Altundag, Kadri
    Bulut, Nilufer
    Dizdar, Omer
    Harputluoglu, Hakan
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 (03) : 329 - 330
  • [5] Amyere M, 2002, INT J MED MICROBIOL, V291, P487
  • [6] [Anonymous], 2004, Molecular Biology of the Cell
  • [7] Aridor M., 2007, ADV DRUG DELIV REV, V59, P8
  • [8] Bareford L., 2007, ADV DRUG DELIV REV, V59, P8
  • [9] Bawarski W. E., 2008, NANOMEDICINE, V4, P4
  • [10] Belting M., 2005, ADV DRUG DELIV REV, V57, P4